BioSpace News Archive

Recent research shows those who had been hospitalized due to COVID-19 might already have a reduced sense of smell and taste, not just for the short term, but possibly for life.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces it has signed LMT Surgical as its new Distributor in Australia and New Zealand.

Affimed N.V., a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release first quarter 2021 results on Thursday, July 1, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, will hold its first Virtual Investor Event, presented by its newly formed executive team.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, provided an update on the clinical advancement of OPC1, its investigational allogeneic oligodendrocyte progenitor cell transplant therapy for the treatment of spinal cord injury.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that the United States Patent and Trademark Office has granted a new patent relating to the Company’s BP1003 program, a novel liposome-incorporated oligodeoxynucleotide inhibitor against Signal Transduction and Activator of Transcription-3.

Merck, known as MSD outside the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy with or without bevacizumab, met its primary endpoints of overall survival and progression-free survival for the first-line treatment of patients with persistent, recurrent or metastatic cervical cancer.

Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to address IgE-mediated food allergy, announced the expansion of its executive leadership team with the appointment of Glenn Reicin, MBA as Chief Financial Officer.

Acasti Pharma Inc. announced its operating and financial results for the fiscal year ended March 31, 2021, and provided an update on its plans to acquire Grace Therapeutics and the ongoing strategic process for CaPre.

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced that it plans to release unaudited financial results for the fourth quarter and full year fiscal 2021 on Monday, June 28, 2021, after the U.S. market close.